Skeletal Muscle Dysfunction in the Development and Progression of Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
The association between the pathogenesis and natural course of nonalcoholic fatty liver disease (NAFLD) and skeletal muscle dysfunction is increasingly recognized. These obesity-associated disorders originate primarily from sustained caloric excess, gradually disrupting cellular and molecular mechanisms of the adipose-muscle-liver axis resulting in end-stage tissue injury exemplified by cirrhosis and sarcopenia. These major clinical phenotypes develop through complex organ-tissue interactions from the earliest stages of NAFLD. While the role of adipose tissue expansion and remodeling is well established in the development of NAFLD, less is known about the specific interplay between skeletal muscle and the liver in this process. Here, the relationship between skeletal muscle and liver in various stages of NAFLD progression is reviewed. Current knowledge of the pathophysiology is summarized with the goal of better understanding the natural history, risk stratification, and management of NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Epidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004 · cited 1×
“A commonly used parameter is appendicular skeletal muscle mass (also referred to as ASM) adjusted for height to yield appendicular skeletal muscle index (also referred to as SMI).(28) Skeletal muscle cross-sectional imaging with magnetic resonance (MR) or computed tomography (CT) has become the gold standard, focusing…”
MethodCruz-Jentoft, A. J., & Sayer, A. A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31138-9 · Cited by 3,905
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Muscles, exercise and obesity: skeletal muscle as a secretory organ
Pedersen, B. K., & Febbraio, M. A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.49 · Cited by 2,909 · cited 3×
“Myostatin is a TGF-b superfamily member and a negative regulator of skeletal muscle mass.(63) Myostatin interferes with mTOR signaling and activates skeletal muscle proteolysis through autophagy and the ubiquitin-proteasome pathway.”
BackgroundSarcopenia: origins and clinical relevance
Rosenberg, I. H. (1997) · The Journal of Nutrition · doi:10.1093/jn/127.5.990s · Cited by 2,399 · cited 1×
“As the name implies, sarcopenia is a condition with diminished skeletal muscle mass, first associated with older age.(23) Today, sarcopenia has a complex meaning as a progressive and generalized disorder seen in various chronic illnesses.”
BackgroundNon-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149 · cited 1×
“Nonalcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder of our time, affecting more than one billion people worldwide and with an estimated 30% prevalence in the adult US population, representing a significant global healthcare burden.(1,2) NAFLD is a manifestation of metabolic syndrome i…”
BackgroundAdipose Tissue as an Endocrine Organ
Ahima, R. S., & Flier, J. S. (2000) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(00)00301-5 · Cited by 1,608
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392 · cited 1×
“NAFLD may progress to cirrhosis, and it confers an increased risk of hepatocellular carcinoma.(4,5) However, prediction of clinical outcomes in NAFLD has proven challenging as environmental and genetic drivers of its progression are not fully identified.”
BackgroundSarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382 · cited 18×
“However, improved muscle function is likely to have a positive impact on liver disease progression and outcomes in all stages of NAFLD.12,17,18,106 Lifestyle modification approaches to skeletal muscle dysfunction in NAFLD There are multiple lines of evidence that lifestyle interventions aimed at improving skeletal mus…”
BackgroundMethodInfluentialEctopic Fat in Insulin Resistance, Dyslipidemia, and Cardiometabolic Disease
Shulman, G. I. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1011035 · Cited by 1,126 · cited 1×
“Obesity-associated leptin resistance results in hyperleptinemia, promoting insulin resistance by upregulating pro-inflammatory cytokines IL-6 and tumor necrosis factor alpha (TNF-a).(60) High leptin levels diminish the anabolic actions of insulin-like growth factor 1 (IGF1) in skeletal muscle and may increase frailty.”
BackgroundThe role of the gut microbiota in NAFLD
Leung, C., Rivera, L., Furness, J. B., & Angus, P. W. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.85 · Cited by 1,020 · cited 1×
“Aberrant host-microbiome interactions may contribute to all NAFLD stages by altering intestinal bile acid metabolism, weakening of the intestinal epithelial barrier, and compromising innate immunity of the gut mucosa as fundamental underlying mechanisms.(87,88) Dysbiosis promotes chronic inflammation and insulin resis…”
BackgroundCopps, K. D., & White, M. F. (2012) · Diabetologia · doi:10.1007/s00125-012-2644-8 · Cited by 1,017 · cited 1×
“In contrast, PKC-mediated activation of protein phosphatase 2A dephosphorylates Akt at a key serine residue.(84) These changes prevent glucose uptake in skeletal muscle and lead to diminished glycogen synthesis and increased gluconeogenesis rates in the liver.”
BackgroundGoodpaster, B. H., Kelley, D. E., Thaete, F. L., He, J., & Ross, R. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.89.1.104 · Cited by 947
Exercise alters gut microbiota composition and function in lean and obese humans
ALLEN, J. M., MAILING, L. J., NIEMIRO, G. M., MOORE, R., COOK, M. D., WHITE, B. A., HOLSCHER, H. D., & WOODS, J. A. (2018) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001495 · Cited by 820 · cited 1×
“Regular exercise is known to modulate the composition and function of gut microbiota, improving bacterial richness and balance towards health-promoting taxa.(108) Physical activity is also critical to mitigate the potential drawbacks of weight management strategies in metabolic dysfunction.”
BackgroundSarcopenia: origins and clinical relevance
Rosenberg, I. H. (2011) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2011.03.003 · Cited by 786
Intermuscular fat: a review of the consequences and causes
Addison, O., Marcus, R. L., LaStayo, P. C., & Ryan, A. S. (2014) · International Journal of Endocrinology · doi:10.1155/2014/309570 · Cited by 656 · cited 1×
“Skeletal muscle disorders in the form of myosteatosis, sarcopenia, and sarcopenic obesity are associated with this process.(10,14,15) Disruption of the complex physiological relationship between skeletal muscle and the liver is mutually detrimental and promotes the progression of NAFLD.”
BackgroundVillareal, D. T., Apovian, C. M., Kushner, R. F., & Klein, S. (2005) · Obesity Research · doi:10.1038/oby.2005.228 · Cited by 579
Montano-Loza, A. J., Angulo, P., Meza-Junco, J., Prado, C. M. M., Sawyer, M. B., Beaumont, C., Esfandiari, N., Ma, M., & Baracos, V. E. (2016) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12039 · Cited by 512 · cited 3×
“00, respectively).(22) Another retrospective analysis done in Kentucky (USA) focused on 207 adult patients who received liver transplantation (male, 68%; mean age, 54±8 years) due to cirrhosis from alcoholrelated liver disease (38.”
BackgroundHeymsfield, S. B., Gonzalez, M. C., Lu, J., Jia, G., & Zheng, J. (2015) · Proceedings of the Nutrition Society · doi:10.1017/s0029665115000129 · Cited by 483
Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis
Koo, B. K., Kim, D., Joo, S. K., Kim, J. H., Chang, M. S., Kim, B. G., Lee, K. L., & Kim, W. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.019 · Cited by 440 · cited 2×
“0%).(45) Moreover, significant fibrosis ($ F2) was more prevalent in subjects with sarcopenia than in those without (45.”
BackgroundAMPK, the metabolic syndrome and cancer
Luo, Z., Saha, A. K., Xiang, X., & Ruderman, N. B. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.12.011 · Cited by 426 · cited 1×
“Adiponectin negatively regulates cell apoptosis via the mammalian target of rapamycin (mTOR) pathway and c-Jun N-terminal kinase (JNK)/caspase 3 pathways.(57) Moreover, adiponectin binding may activate ceramidases that degrade harmful ceramide and its derivatives.”
BackgroundGut Microbiota, Muscle Mass and Function in Aging: A Focus on Physical Frailty and Sarcopenia
Ticinesi, A., Nouvenne, A., Cerundolo, N., Catania, P., Prati, B., Tana, C., & Meschi, T. (2019) · Nutrients · doi:10.3390/nu11071633 · Cited by 418 · cited 1×
“Dysbiosis promotes chronic inflammation and insulin resistance, at least in part via modulation of the skeletal muscle composition and function.(89) Although there is no direct evidence of a link between human gut microbiota composition and sarcopenia, experimental studies indicate that administration of Faecalibacter…”
BackgroundHong, H. C., Hwang, S. Y., Choi, H. Y., Yoo, H. J., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., Choi, D. S., & Choi, K. M. (2014) · Hepatology · doi:10.1002/hep.26716 · Cited by 385 · cited 1×
“In a prospective observational cohort of 452 healthy adults from the Korean Sarcopenic Obesity Study, individuals with sarcopenia (defined by having a DXA-estimated skeletal muscle mass index 1 standard deviation below the reference) had significantly greater body mass index (BMI), waist circumference, total body fat…”
BackgroundMyostatin/activin pathway antagonism: molecular basis and therapeutic potential
Han, H. Q., Zhou, X., Mitch, W. E., & Goldberg, A. L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.019 · Cited by 314 · cited 1×
“Myostatin interferes with mTOR signaling and activates skeletal muscle proteolysis through autophagy and the ubiquitin-proteasome pathway.(65) Myostatin promotes liver inflammation and fibrosis via activin IIbr receptors on hepatic stellate cells.”
BackgroundRole of intramyocelluar lipids in human health
Coen, P. M., & Goodpaster, B. H. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.05.009 · Cited by 252 · cited 2×
“Intramyocellular fat is not necessarily abnormal as it serves as an energy source to fuel muscle contraction.(8,20) The”
BackgroundIrisin is inversely associated with intrahepatic triglyceride contents in obese adults
Zhang, H.-J., Zhang, X.-F., Ma, Z.-M., Pan, L.-L., Chen, Z., Han, H.-W., Han, C.-K., Zhuang, X.-J., Lu, Y., Li, X.-J., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.030 · Cited by 234 · cited 1×
“One of the molecular targets of irisin is the nuclear hormone receptor PPAR-a, which explains its stimulatory impact on fatty acid oxidation.(68) Myonectin, another exercise-inducible myokine, promotes the uptake of free fatty acids in adipose tissue and the liver.”
BackgroundPolyzos, S. A., & Margioris, A. N. (2018) · Hormones · doi:10.1007/s42000-018-0049-x · Cited by 212
Reference Values for Skeletal Muscle Mass – Current Concepts and Methodological Considerations
Walowski, C. O., Braun, W., Maisch, M. J., Jensen, B., Peine, S., Norman, K., Müller, M. J., & Bosy-Westphal, A. (2020) · Nutrients · doi:10.3390/nu12030755 · Cited by 200 · cited 1×
“There are many methods to measure skeletal muscle mass and many ways to report the findings, creating challenges in the literature.(27) A commonly used parameter is appendicular skeletal muscle mass (also referred to as ASM) adjusted for height to yield appendicular skeletal muscle index (also referred to as SMI).”
MethodKadi, F. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.118 · Cited by 200
Kim, G., Lee, S., Lee, Y., Jun, J. E., Ahn, J., Bae, J. C., Jin, S., Hur, K. Y., Jee, J. H., Lee, M., et al. (2018) · Hepatology · doi:10.1002/hep.30049 · Cited by 198 · cited 2×
“These relationships persisted even after adjusting for baseline skeletal muscle mass index, suggesting that skeletal muscle mass impacts NAFLD’s natural history.(46) In a prospective cross-sectional cohort study from China with 5,132 participants aged 18 to 80 years, sonographically-diagnosed”
BackgroundGamas, L., Matafome, P., & Seiça, R. (2015) · Journal of Diabetes Research · doi:10.1155/2015/359159 · Cited by 114
Muscle-associated triglyceride measured by computed tomography and magnetic resonance spectroscopy
Larson‐Meyer, D. E., Smith, S. R., Heilbronn, L. K., Kelley, D. E., Ravussin, E., Newcomer, B. R., & The Look AHEAD Adipose Research Group (2006) · Obesity · doi:10.1038/oby.2006.10 · Cited by 111
Bariatric Surgery Outcomes in Sarcopenic Obesity
Mastino, D., Robert, M., Betry, C., Laville, M., Gouillat, C., & Disse, E. (2016) · Obesity Surgery · doi:10.1007/s11695-016-2102-7 · Cited by 79
A complex role of activin A in non-alcoholic fatty liver disease
Yndestad, A., Haukeland, J. W., Dahl, T. B., Bjøro, K., Gladhaug, I. P., Berge, C., Damås, J. K., Haaland, T., Løberg, E. M., Linnestad, P., et al. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.318 · Cited by 75 · cited 1×
“Myostatin promotes liver inflammation and fibrosis via activin IIbr receptors on hepatic stellate cells.(66) Irisin is an exercise-inducible myokine with the ability to increase total body energy expenditure by stimulating “browning” and uncoupling protein-1 expression in subcutaneous white adipose tissue and thus imp…”
BackgroundNonalcoholic fatty liver disease in the over-60s: Impact of sarcopenia and obesity
Wijarnpreecha, K., Panjawatanan, P., Aby, E., Ahmed, A., & Kim, D. (2019) · Maturitas · doi:10.1016/j.maturitas.2019.03.016 · Cited by 32
Cited by
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Sawada, K., Chung, H., Softic, S., Moreno-Fernandez, M. E., & Divanovic, S. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.009 · Cited by 139
Targher, G., Mantovani, A., & Byrne, C. D. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00338-7 · Cited by 121
Nachit, M., Kwanten, W. J., Thissen, J.-P., Op De Beeck, B., Van Gaal, L., Vonghia, L., Verrijken, A., Driessen, A., Horsmans, Y., Francque, S., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.037 · Cited by 114
Metadata
- Authors
- Altajar, S., & Baffy, G.
- Venue
- Journal of Clinical and Translational Hepatology
- Publisher
- Xia & He Publishing
- Published
- 2020-10-15
- Volume
- 8
- Issue
- 4
- Pages
- 1-10
- ISSN
- 2225-0719 (ISSN-L)
- 2310-8819
- OpenAlex
- W3092691115
- Cited by
- 72
- References
- 37
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.